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alpha interferon (IFN-a)-based therapies. However, the
antiviral mechanism of the cytokine against HCV remains
to be understood.
Methods: Established Huh7.5-BST2 cell lines were infected
with HCV at low (0.05) and high (3) MOI. Fluorescent
immunostaining, western blot, northern blot and viral titer
detection were used to analyze the dynamics of HCV
infection and virion production. siRNA targeting the mRNA
of BST2 was transfected into IFN-a treated Huh7.5 cells to
evaluate the role of BST2 on the effect of IFN-a against
HCV. High density (100% conﬂuent) and low density (25%
conﬂuent) cells were infected with HCV (MOI 0.05) with or
without CD81 antibody to test if BST2 inhibits HCV cell to
cell spread.
Results: We found that expression of an IFN-induced
cell membrane protein BST2 in Huh7.5 cells did not
apparently affect the efﬁciency of HCV infection and
genome replication, but signiﬁcantly reduced the yield
of virion production from the infected cells. In addition,
BST2 also dramatically inhibited the cell-to-cell transmission
of HCV in cultured Huh7.5 monolayers. Furthermore,
we demonstrated that inhibition of IFN-a-induced BST2
expression in Huh7.5 cells by siRNA technology compromised
the antiviral response of the cytokine against HCV.
Conclusions: Our results imply that BST2 is a functional
mediator of IFN response against HCV infection and inhibits
the release of HCV virions, which presumably buds from the
endoplasmic reticulum, but not plasma membrane.
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Full length NS2TP gene was ampliﬁed by PCR,
using prokaryotic expression plasmid pET32a(+)-NS2TP as
template, and cloned into the eukaryotic expressing
vector pEGFP-C1by DNA recombination technique. The
recombinant plasmid was identiﬁed by restriction enzyme
digestion, polymerase chain reaction and direct sequencing.
Then both the recombinant plasmid pEGFP-C1-NS2TP and
the control vector pEGFP-C1 were used to transfect HepG2
cell with Lipofectin 2000. After 30 h, the cells were
collected and NS2TP gene expression was proved by Western
blot analysis. Under the same culture conditions, both of
the HepG2 cell transfected with pEGFPC1-NS2TP and pEGFP-
C1 were collected after 30 h postransfection. Celltiter-Glo
luminescent cell viability assay showed that the growth of
hepG2 cells transfected with NS2TP gene was dramatically
inhibited compared with the parent hepG2 cells. These
results indicated that NS2TP could affect the cell growth of
HepG2 cell.
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China
Objective: To study the impact of gender on virologic
responses rates in genotype 1 CHC patients.
Methods: A matched retrospective cohort on 630 patients
treated with peginterferon and ribavirin was conducted.
The virologic response rates were compared between male
and female. The inﬂuential factors on SVR were studied
by multivariate analysis. In patients aged <40 years group,
the SVR rate of female was signiﬁcantly higher than that
of male (75.0%, 75/100 vs 54.0%, 54/100; P = 0.002); in
patients aged 40 50 years group, there was no signiﬁcant
difference in the SVR rate between male and female
(50.5%, 53/105 vs 54.3%, 57/105; P = 0.580); in patients aged
51 60 years group, the SVR rate of female was signiﬁcantly
lower than that of male (33.6%, 37/110 vs 48.2%, 53/110;
P = 0.028). In multivariate logistic regression analysis, the
independent factors associated with SVR of patients aged
51 60 years were sex (P = 0.013), 80% of planned ribavirin
dose (P = 0.008) and presence of RVR (P = 0.001).
Conclusions: In patients aged <40 years group, the SVR rate
of female is higher than that of male; in patients aged
40 50 years group, they share similar SVR rates; in patients
aged 51 60 years group the SVR rate of female is lower than
that of male.
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elderly patients with chronic hepatitis C
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China
To evaluate the efﬁcacy of treatment with peginterferon
alfa-2a and ribavirin in elderly CHC patients and study the
inﬂuential factors related to SVR. The patients were divided
into two groups according to age: patients aged 65 years
(n = 140) and patients aged <65 years (n = 277). The virologic
response rates of two groups were compared.
Results: For genotype 1, patients aged 65 years had
signiﬁcantly higher relapse rate (50.0%, 42/84 vs 29.2%,
52/178; P = 0.001) and lower SVR rate (40.0%, 42/105 vs
60.0%, 126/210; P = 0.001) than patients aged <65 years.
For genotype 1, in patients aged 65 years, the SVR rate
of female patients was signiﬁcantly lower than that of
male patients (28.6%, 12/42 vs 47.6%, 30/63; P = 0.004).
In multivariate logistic regression analysis, the independent
factors associated with SVR of patients aged 65 years were
sex (P = 0.020), genotypes (P = 0.005), ribavirin reduction or
discontinuation (P = 0.009) and presence of rapid virologic
response (RVR) (P = 0.001).
Conclusions: The SVR rate of patients aged  65 years with
genotype 1 is low. Among patients 65 years old, genotype
2 patients and genotype 1 patients with a low baseline viral
load or achieving RVR or male may beneﬁt from combination
therapy.
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Objective: In 2009, three works published almost at
the same time studied the association between single
nucleotide polymorphisms near IL28B gene region and
treatment effect of pegylated-interferon (PegIFN) and
ribavirin (RVB) in HCV-infected patients. Many studies on
this issue with different HCV genotype and ethnic subjects
published subsequently. However, the conclusions about the
role of these polymorphisms are not identical. The aim
of this study was to quantify the impact of the IL28B
polymorphisms on the effect of HCV standard treatment
using meta-analysis based method.
Poster Presentations, Poster Session End Stage Liver Diseases and Complications S87
Methods: Works studying the association between
polymorphisms of rs12979860 or rs8099917 and the impact
on HCV treatment were retrieved in PubMed. After
evaluated independently by two researchers, data on
the distribution of patients reaching sustained virological
response (SVR) in different genotypes of the qualiﬁed studies
was abstracted and the summary ORs were calculated using
the relevant effect model of meta-analysis based on the
heterogeneity results in Stata 10.0 software.
Results: Twenty three studies that met the inclusion
criteria were included in the analysis, of which 9 were
on rs12979860, 8 on rs8099917 and 6 on both. Comparing
to subjects with the rs12979860 CT/TT genotype, HCV
infected patients carrying the CC genotype were more
likely to reach SVR after the PegIFN-RVB therapy (OR=3.18,
95%CI: 2.33 4.35). A similar result was observed in subjects
carrying rs8099917 TT genotype comparing to TG/GG
(OR=2.37, 95%CI: 1.73 3.23). As to the subgroup analysis,
those positive results above could only be observed in
the HCV genotype 1 group, but not in subjects infecting
HCV genotype non-1. The publication bias analysis had no
statistically signiﬁcant results.
Conclusion: rs12979860 and rs8099917 were involved in
the effects of HCV treatment with PegIFN-RVB, but this
impact could only be observed in relatively difﬁcult-to-treat
genotype 1 subjects.
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Thyroid dysfunction can be affected as a complication of
interferon therapy due to HCV infection. The aims of the
present study were to investigate the effect of interferon
therapy on the thyroid function on Egyptian patients with
HCV infection.
The study includes 60 HCV infected patients with normal
baseline levels of TSH. The patients receive a subcutaneous
pegylated interferon alfa-2b weekly in addition to oral
ribavirin (1000 1200mg/d). The patients were suspected
to complete history and clinical examination, with special
emphasis to hepatic and thyroid disorders. Before the start
of interferon therapy, serum TSH, thyroglobulin-Ab (TG-Ab)
and antiperooxidase antibodies (TPO-Ab) were measured.
Three months after interferon therapy serum levels of TSH
were performed to all patients, patients with abnormal TSH
were suspected to the measurements of FT3, FT4, TPO-Ab,
TG-Ab and thyroid stimulating immunoglobulin levels (TSI).
After 3 months of interferon therapy, 48 patients (80%)
had normal TSH and 12 patients (20%) had abnormal
TSH. Out of 12 patients had abnormal TSH, 10 patients
(16.6%) had high serum levels of TSH (hypothyroidisms),
while the remaining 2 patients (3.4%) had low serum
levels of TSH (hyperthyroidism). Out of 10 patients with
hypothyroidism, 6 patients (10%) had overt hypothyroidism
and 4 patients (6.6%) had subclinical hypothyroidism. All
patients with abnormal TSH had a signiﬁcant higher levels
of TG-Ab, TPO-Ab and STI. Out of two patients with
hyperthyroidism, one patient presented by clinical pictures
of overt hyperthyroidism, while the other patient presented
by subclinical hyperthyroidism.
In conclusion, the incidence of thyroid dysfunction during
pegylated interferon therapy in patients with HCV is 20%;
hypothyroids was more common than hyperthyroidism. The
patients most at risk for thyroid dysfunctions are people
with preexisting TPO-Abs. Patients with HCV infection
under pegylated interferon and ribavirin therapy should
be screened for thyroid dysfunction before and during
treatment.
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Introduction: CLD is one of the most common health
problems in Egypt due to the prevalence of bilharaiasis
as well as viral hepatitis. The way in which the family copes
with and adapts to chronic illness of one of its members has
a strong impact on the physical and psychosocial well-being
of all members and on the shape and duration of the clinical
course of the illness itself. The family doctor therefore
should be able to evaluate the families’ adaptation to
illness and to promote successful coping strategies where
necessary. The aim of this study is to improve family
function of patients with CLD through detection of family
dysfunction. The detection of family function is the ﬁrst
step in this regard.
Methodology: This study was cross sectional descriptive
study carried in communicable disease and research center
in Suez, its target population was adult patients of
both sexes with CLD. Total number of the sample was
233 patients. Each patient was subjected to the following:
1) Personal, social, geographic assessment.2) History and
physical examination. 3) Biochemical testing for Liver
function evaluation. The Assessment of family function was
done by using (FACESII).
Results: Current study showed that regarding to cohesion,
it was found that 70.4% of patients were balanced while
29.6% were extreme. Regarding to adaptability 66.1% were
balanced, while 33.9% were extreme. It found that 53.6% of
the patients were dysfunction families (mid range, extreme
family function), while 46.6% were balanced (function
families).
Conclusion: The present study concluded that, family
dysfunction is a considerable problem among patient with
CLD. It was no signiﬁcantly associated with almost all socio-
demographic except age of the patient, there were also
no signiﬁcantly associated with severity of CLD, number of
Symptoms and sign of CLD except gynecomastia (for males)
and abdominal swelling.
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Background and Objective: To explore the curative effect
of Transmetil in the treatment for patients with with
depressed emotion and Chronic liver failure in hepatitis B.
Methods: All 49 patients with Chronic liver failure in
hepatitis B were randomly divide into the experiment group
(medical synthetic treatments combined with Transmetil,
n = 32) and the control group (only medical synthetic
